Lamivudine Aurobindo (Lamivudine)

Lamivudine is a nucleoside analog that is taken up by cells and phosphorylated to its active triphosphate form. This active metabolite competes with natural nucleotides for the active site of HIV reverse transcriptase and hepatitis B virus DNA polymerase, causing premature termination of viral DNA chains and blocking replication.

The dosage of Lamivudine Aurobindo is determined by the prescribing healthcare professional based on the individual’s clinical condition, weight, renal function and other factors. Patients should follow the dose and schedule provided by their prescriber and not adjust the regimen on their own.

Safety data for lamivudine in pregnancy and lactation are limited. The drug may be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should assess each case individually and discuss potential risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other antiretrovirals for optimal viral suppression. Compared with some alternatives, it has a favorable safety profile and convenient oral dosing, but resistance patterns and individual patient factors may influence the choice of regimen.

Lamivudine Aurobindo should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight and extreme temperature fluctuations to maintain potency throughout its shelf life.

Lamivudine Aurobindo is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically advised by a healthcare professional.

Serious adverse events, although rare, include lactic acidosis, severe hepatotoxicity and pancreatitis. Patients should be monitored for signs such as unexplained fatigue, abdominal pain, jaundice or rapid weight loss, and any concerning symptoms should prompt immediate medical evaluation.

Lamivudine Aurobindo should be avoided in patients with known hypersensitivity to lamivudine or any of the tablet excipients. Caution is also advised for individuals with severe renal impairment, active liver disease, or those taking medications that have major interaction risks, unless close monitoring is possible.